"We unveils baseball managers are committed petco park events devises to bringing the hope of Soliris to more patients withPNH in additional countries around the world, as we drive forward in parallel toevaluate the potential of Soliris as a treatment for patients with other severe,ultra-rare complement-mediated diseases." Research and Development:Prix Galien in FranceIn June, as previously announced, Soliris received the 2009 Prix Galien Award inFrance for the most innovative drug for rare disease. Moreover, we werepleased to receive the prestigious Prix Galien Award in France, which furtheracknowledges the innovation of Soliris as the first-in-class terminalcomplement-inhibitor," said Leonard Bell, M.D., Chief Executive Officer ofAlexion. "In the second quarter, we again provided the clinical benefit of Soliris tosignificant numbers of new patients in the U.S and Europe. The Company continued to significantly reduce levels of long-term debt duringthe quarter.
Alexion debt holders elected to exchange their notes, resulting ina reduction in the convertible debt balance from $97 million at March 31, 2009to $10 million at June 30, 2009 baseball season tickets . Additionally, as previously announced, theCompany has arranged to prepay, without penalty, the $44 million, 9.1 percentmortgage loan on its Rhode Island manufacturing facility petco park schedule . The prepayments willbe made over three quarters, and the Company expects to fund these paymentsmainly through cash flow from operations pro baseball tickets . At the end ofthe quarter, the outstanding borrowings on the Company's revolving creditfacility were zero rod beck . Balance Sheet:As of June 30, 2009, the Company had $147.6 million in cash, cash equivalentsand restricted cash, compared to $140.8 million at March 31, 2009. Operating expenses for Q2 2009 included $6.9 million of share-basedcompensation expense, compared to $6.0 million in Q2 2008.
SG&A expenses were $42.7 million for Q2 2009, compared to$32.9 million for Q2 2008 baseball tickets . The increase in GAAP SG&A expenses primarilyreflected costs associated with the expansion of the Company's operations in theU.S., Europe and other countries to support the ongoing commercial launch ofSoliris san diego padres . The increase inGAAP R&D costs in Q2 2009 was primarily the result of the Company's expandedclinical studies tony gwynn autographed baseball . On a GAAP basis, total operating expenses for Q2 2009 were $61.0 million,compared to $49.7 million for Q2 2008 tony gwynn signed baseball . R&D expenses for Q2 2009 were $18.3million, compared to $16.8 million for the year-ago quarter. GAAP earnings per share in Q2 2009 included anon-cash charge of $3.4 million, or $0.04 per share, associated with theexchange of convertible notes during the quarter.
Second Quarter 2009 GAAP Financial Results:Alexion reported GAAP net income for the second quarter of 2009 of $16.8million, or $0.19 per share, compared to GAAP net income of $2.4 million, or$0.03 per share, for Q2 2008 cubs rooftop . The increase in non-GAAP SG&A expenses primarily reflectedcosts associated with the expansion of the Company's operations in the U.S.,Europe and other countries to support the ongoing commercial launch of Soliris petco park events . Non-GAAP selling, general, andadministrative (SG&A) expenses for Q2 2009 were $37.6 million, compared to $28.4million for Q2 2008 petco park schedule . The increase in R&D costs in Q2 2009 was primarily the resultof the Company's expanded clinical studies pro baseball tickets .
Alexion's non-GAAP total operating expenses for Q2 2009 were $54.0 million,compared to $43.7 million for Q2 2008 jake peavy . Non-GAAP research and development (R&D)expenses for Q2 2009 were $16.5 million, compared to $15.3 million for theyear-ago quarter rod beck . Non-GAAP earnings per share in Q2 2009 included a non-cash charge of$3.4 million, or $0.04 per share, associated with the exchange of convertiblenotes during the quarter san diego padres . The following summary table is provided forinvestors' convenience .